Clinical reference Biomarker Directory
Back to directory

CALCA

Established

Calcitonin is the primary tumor marker for medullary thyroid carcinoma, guiding surgery and recurrence monitoring.

Also known as Calcitonin thyrocalcitonin
In plain language

Calcitonin is a thyroid hormone that becomes a strong warning sign for a rare thyroid cancer called medullary thyroid carcinoma when it's too high. Doctors use it before surgery to help plan the operation, and afterward to check the cancer is gone.

Biomarker & context

CALCA encodes calcitonin, a hormone produced by parafollicular C-cells of the thyroid that regulates calcium metabolism. Its main clinical value is as the most sensitive and specific biomarker for medullary thyroid carcinoma (MTC), a cancer arising from these same C-cells.

What it indicates

Elevated basal serum calcitonin strongly suggests MTC; levels above 100 pg/mL are highly suspicious, while intermediate elevations (10-100 pg/mL) may reflect benign C-cell hyperplasia rather than cancer, creating diagnostic ambiguity that sometimes requires calcium stimulation testing to clarify.

Diagnosis & clinical testing

Measured via serum immunoassay; a 2025 study established updated basal calcitonin thresholds for predicting the extent of lymph node metastasis, helping surgeons plan how extensive a neck dissection should be, since older thresholds relied on outdated lab testing methods.

Guiding treatment

Postoperative calcitonin normalization confirms successful tumor resection; persistently elevated or rising calcitonin after surgery indicates residual or recurrent disease and guides further imaging and treatment decisions. Routine population-wide calcitonin screening of thyroid nodule patients is not recommended by ATA guidelines despite improving detection, due to cost-effectiveness concerns.

Clinical significance

Highly sensitive and specific for MTC; intermediate elevations require additional testing to distinguish cancer from benign hyperplasia.

References
  1. Broecker-Preuss, M., et al. (2023). Update on Calcitonin Screening for Medullary Thyroid Carcinoma. Cancers.
  2. JAMA Otolaryngology. (2025). Updated Thresholds of Basal Calcitonin Level and Extent of Lymph Node Metastasis in MTC.